Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Operating Leases (2023 - 2026)

Prelude Therapeutics' Operating Leases history spans 4 years, with the latest figure at $15.0 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 2.01% to $15.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.0 million, a 2.01% decrease, with the full-year FY2025 number at $15.0 million, down 1.83% from a year prior.
  • Operating Leases hit $15.0 million in Q1 2026 for Prelude Therapeutics, down from $15.0 million in the prior quarter.
  • Over the last five years, Operating Leases for PRLD hit a ceiling of $18.1 million in Q3 2024 and a floor of $15.0 million in Q1 2026.
  • Historically, Operating Leases has averaged $15.5 million across 4 years, with a median of $15.3 million in 2024.
  • Biggest five-year swings in Operating Leases: dropped 0.53% in 2024 and later dropped 16.59% in 2025.
  • Tracing PRLD's Operating Leases over 4 years: stood at $15.4 million in 2023, then decreased by 0.53% to $15.3 million in 2024, then fell by 1.83% to $15.0 million in 2025, then dropped by 0.56% to $15.0 million in 2026.
  • Business Quant data shows Operating Leases for PRLD at $15.0 million in Q1 2026, $15.0 million in Q4 2025, and $15.1 million in Q3 2025.